Fresh off a $34 million Series D fundraise, Precision Therapeutics Inc. is planning to launch a “genomics” product sometime in 2011.
iCAD Inc. (NSDQ:ICAD) won a contract with the U.S. Defense and Veterans Affairs departments to sell its cancer detection devices to the 400 treatment facilities under the agencies’ auspices.
The Nashua, N.H.-based company, which designs image analysis equipment for the early identification of cancer, entered the agreement with the Defense Supply Center to provide federal healthcare facilities, including Veteran’s Administration and Dept. of Defense hospitals with its computer-aided mammography technology for.
Predictive Biosciences appointed two vice presidents and expanded its sales force as it prepares for the launch of a bladder cancer test.
James Groves was hired as vice president of lab operations and Mark Smith as vice president of information technology. Groves will help oversee Predictive’s OncoDiagnostic Laboratory, the company’s Cleveland-based commercial division and a recent acquisition. Smith is the former VP of information technology at Worcester, Mass.-based Athena Diagnostics.
HistoRx Inc. has landed a big boost for its cancer prognosis methods from the U.S. Patent and Trademark Office, as the New Haven, Conn.-based diagnostics firm was granted an exclusive license to its cancer treatment patent.
Ethicon Endo-Surgery Inc. is entertaining an offer from a private equity-backed holding company for its breast care business, including the MammoTome biopsy system.
The Johnson & Johnson (NYSE:JNJ) subsidiary has until June 15 to decide whether to accept the offer from Devicor Medical Products, a portfolio company of GTCR Golder Rauner LLC. Specific terms of the offer were not disclosed.
HistoRx Inc., a cancer therapy diagnostics firm based in New Haven, won a $1.5 million loan from Connecticut’s quasi-public life sciences initiative.
HistoRx is developing what it calls AQUA, technology designed to assess the potential effectiveness of cancer drugs and predict patients’ responses to the treatments. The system uses fluorescence-based image analysis and automated microscopy to measure protein molecules. Connecticut Innovations, the quasi-public equivalent of the Mass. Life Sciences Center, is loaning the company $1.5 million to build out laboratory space and buy equipment.
Hologic Inc. (NSDQ:HOLX) agreed to pay $12.5 million to Johnson & Johnson (NYSE:JNJ) subsidiary Ethicon Endo-Surgery to settle a pair of patent infringement cases involving breast biopsy technology.
Ethicon sued Hologic in 2007 in Ohio and in 2009 in Delaware, accusing the Bedford, Mass.-based women’s health products maker of violating a quartet of patents related to Ethicon’s Mammotome breast biopsy system with Hologic’s ATEC system, and of violating false advertising laws.
Exact Sciences Corp. (NSDQ:EXAS) posted fourth-quarter sales of $1.2 million for the three months ended Dec. 31, 2009, compared with negative revenues of $109,000 during the same period in 2008. Net losses narrowed 13.9 percent to $1.8 million, compared with $2.1 million during Q4 2008:
BioSphere Medical Inc. (NSDQ:BSMD) managed to cut its losses in half during 2009, ending the year with a 7 percent sales increase.
The Rockland, Mass.-based microsphere maker reported a net loss of $293,000 on $8.4 million in sales during the three months ended Dec. 31, 2009, compared to a $1.7 million loss on $7.2 million in sales for the same period in 2008.
Varian Medical Systems (NYSE:VAR) posted first-quarter sales of $540.9 million, up 6.3 percent compared with $508.7 million during the same period last year. Net earnings rose 14.5 percent to $78.8 million, compared with $68.8 million during Q1:
Varian Medical Systems Reports Results for First Quarter of Fiscal Year 2010
Net earnings per diluted share from continuing operations rise 13 percent to $0.63; revenues rise 6 percent to $541 million; company raises guidance for fiscal year
Perceptive Informatics tapped a lymphoma expert from Georgetown University Hospital for its scientific advisory board.
The Boston-based Parexel International Corp. (NSDQ:PRXL) subsidiary, which makes software to manage medical imaging data for clinical trials, named Dr. Bruce Cheson to its medical imaging scientific advisor team. Cheson leads the hematology program at Georgetown’s Lombardi Comprehensive Cancer Center and is an expert on lymphoma treatment.